contact

Talk to the Team

Trevarx is currently pursuing its Series A to advance AlphaPARP through IND-enabling work, first-in-human dosimetry, and Phase 1 dose escalation and expansion. We welcome conversations with venture capital funds, strategic partners, and scientific stakeholders in the targeted alpha radiopharmaceutical space.

Let's Discuss

To learn more about Trevarx’s platform, pipeline, and current financing round, please reach out using the form below. A member of the team will follow up.

Please do not submit patient information, personal health information, confidential business information, trade secrets, proprietary ideas, or unsolicited invention disclosures through this form. Information submitted through this form will be treated as non-confidential unless Trevarx has entered into a separate written confidentiality agreement with you.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Jean Cho

CEO / Founder
jeancho@trevarx.com

Trevarx Biomedical, Inc.

2929 Arch Street, Floor 3
Philadelphia, PA 19104